83 related articles for article (PubMed ID: 26285064)
1. Depot delivery of dexamethasone and cediranib for the treatment of brain tumor associated edema in an intracranial rat glioma model.
Ong Q; Hochberg FH; Cima MJ
J Control Release; 2015 Nov; 217():183-90. PubMed ID: 26285064
[TBL] [Abstract][Full Text] [Related]
2. Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema.
Tamargo RJ; Sills AK; Reinhard CS; Pinn ML; Long DM; Brem H
J Neurosurg; 1991 Jun; 74(6):956-61. PubMed ID: 2033457
[TBL] [Abstract][Full Text] [Related]
3. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
[TBL] [Abstract][Full Text] [Related]
4. [Clinical control trial of methylprednisolone and dexamethasone in treatment of intracranial tumor edema].
Ding X; Mao B; Ju Y; Liu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):327-9. PubMed ID: 12947730
[TBL] [Abstract][Full Text] [Related]
5. The effect of dexamethasone on the uptake of p-boronophenylalanine in the rat brain and intracranial 9L gliosarcoma.
Morris GM; Micca PL; Coderre JA
Appl Radiat Isot; 2004 Nov; 61(5):917-21. PubMed ID: 15308168
[TBL] [Abstract][Full Text] [Related]
6. Effect of a chemical delivery system for dexamethasone (Dex-CDS) on peritumoral edema in an experimental brain tumor model.
Siegal T; Soti F; Biegon A; Pop E; Brewster ME
Pharm Res; 1997 May; 14(5):672-5. PubMed ID: 9165542
[No Abstract] [Full Text] [Related]
7. Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Lobo MR; Kukino A; Tran H; Schabel MC; Springer CS; Gillespie GY; Grafe MR; Woltjer RL; Pike MM
PLoS One; 2015; 10(12):e0144488. PubMed ID: 26645398
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of local delivery of dexamethasone on experimental brain tumors and peritumoral brain edema.
Ikeda Y; Carson BS; Lauer JA; Long DM
J Neurosurg; 1993 Nov; 79(5):716-21. PubMed ID: 8410250
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin-releasing factor decreases vasogenic brain edema.
Tjuvajev J; Uehara H; Desai R; Beattie B; Matei C; Zhou Y; Kreek MJ; Koutcher J; Blasberg R
Cancer Res; 1996 Mar; 56(6):1352-60. PubMed ID: 8640825
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H
J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228
[TBL] [Abstract][Full Text] [Related]
11. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Scott AW; Tyler BM; Masi BC; Upadhyay UM; Patta YR; Grossman R; Basaldella L; Langer RS; Brem H; Cima MJ
Biomaterials; 2011 Apr; 32(10):2532-9. PubMed ID: 21220172
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal assessment of regional directed delivery in a rodent malignant glioma model.
Kondo A; Goldman S; Lulla RR; Mania-Farnell B; Vanin EF; Sredni ST; Rajaram V; Soares MB; Tomita T
J Neurosurg Pediatr; 2009 Dec; 4(6):592-8. PubMed ID: 19951051
[TBL] [Abstract][Full Text] [Related]
13. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth.
Gao H; Yang Z; Zhang S; Cao S; Pang Z; Yang X; Jiang X
J Control Release; 2013 Dec; 172(3):921-8. PubMed ID: 24120853
[TBL] [Abstract][Full Text] [Related]
14. Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
Lobo MR; Wang X; Gillespie GY; Woltjer RL; Pike MM
PLoS One; 2014; 9(12):e114110. PubMed ID: 25490024
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
[TBL] [Abstract][Full Text] [Related]
16. Factors responsible for the retention of fluid in human tumor edema and the effect of dexamethasone.
Bodsch W; Rommel T; Ophoff BG; Menzel J
J Neurosurg; 1987 Aug; 67(2):250-7. PubMed ID: 3598684
[TBL] [Abstract][Full Text] [Related]
17. Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Lobo MR; Green SC; Schabel MC; Gillespie GY; Woltjer RL; Pike MM
Neuro Oncol; 2013 Dec; 15(12):1673-83. PubMed ID: 24092859
[TBL] [Abstract][Full Text] [Related]
18. The role of minocycline in the treatment of intracranial 9L glioma.
Weingart JD; Sipos EP; Brem H
J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Farrar CT; Kamoun WS; Ley CD; Kim YR; Catana C; Kwon SJ; Rosen BR; Jain RK; Sorensen AG
PLoS One; 2011 Mar; 6(3):e17228. PubMed ID: 21390238
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
